Join
Live feed
·
NEWSReleasevia Quantisnow
Merck & Company Inc. logo
Prelude Therapeutics Incorporated logo

Prelude Therapeutics Collaborates With Merck To Evaluate PRT3789 Combined With KEYTRUDA (Pembrolizumab) In Patients With SMARCA4-Mutated Cancers

ByQuantisnow·Wall Street's wire, on your screen.
MRK· Merck & Company Inc.PRLD· Prelude Therapeutics Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRK (Merck & Company Inc.), PRLD (Prelude Therapeutics Incorporated) and more on Quantisnow.